Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

We have 19 Toxicology (pharmacology) PhD Projects, Programmes & Scholarships

Discipline

Discipline

Medicine

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


Toxicology (pharmacology) PhD Projects, Programmes & Scholarships

We have 19 Toxicology (pharmacology) PhD Projects, Programmes & Scholarships

Pharmacological and toxicological effects of pollutants on the cardiovascular system

Faculty of Pharmacy, Charles University, Department of Pharmacology and Toxicology. The majority of the world's population lives in medium or large cities where human activities (industry, transport, etc.) have a direct impact on the production of pollutants. Read more

Molecular Mechanisms of Receptor and Ion Channel Regulation in Pain and Inflammation

Are you ready to delve into the captivating world of molecular signaling and unravel the mysteries of the cardiovascular and nervous systems? We are thrilled to offer an exhilarating PhD opportunity at the forefront of scientific exploration. Read more

Therapeutic resolution of pulmonary arterial hypertension (PAH) by natural products

  Research Group: Pharmacology and Experimental Therapeutics
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death. Read more

Therapeutic resolution of coronavirus (COVID-19) diseases by natural products

  Research Group: Pharmacology and Experimental Therapeutics
Coronavirus now labelled as Covid-19 has become a global pandemic affecting around 200 countries. Currently neither any cure nor any vaccine for Covid-19 has been established. Read more

Polysialyltransferases as a target in metastatic cancer

  Research Group: Institute of Cancer Therapeutics
Polysialic acid plays an essential role in neuronal development, but by adulthood is absent from the human body. Its biosynthesis is regulated by two polysialyltransferases. Read more

Development of a personalized therapy for pulmonary arterial hypertension (PAH)

  Research Group: Pharmacology and Experimental Therapeutics
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death. Read more

Design, synthesis and evaluation of protease-activated anti-cancer prodrugs

  Research Group: Institute of Cancer Therapeutics
Matrix metalloproteinases (MMPs) are a family of endoproteases that are overexpressed in tumours and play crucial roles in many tumourigenic processes, not least tumour invasion and angiogenesis. Read more

Design, synthesis and evaluation of novel polysialyltransferase inhibitors as anti- metastatic agents

  Research Group: Institute of Cancer Therapeutics
Polysialic acid plays an essential role in neuronal development, but by adulthood is absent from the human body. Its biosynthesis is regulated by two polysialyltransferases (polySTs). Read more

The epigenomic, transcriptional and diagnostic architecture of neurodevelopmental disorders caused by exposure to maternal infection

A fundamental unknown in understanding mechanisms of disease, and therefore improving therapy, is how stressors experienced during critical developmental periods influence the genesis or ‘programming’ of adult disease (Estes & McAllister 2016). Read more

Personalising cancer treatment with tumour evolution modelling using AI-based genomics biomarkers and PK/PD

Tumour heterogeneity is a major problem limiting the efficacy of targeted oncological therapies. Most advanced tumours eventually become resistant to the treatments, ultimately making the patient succumb to metastatic disease. Read more

Network-based predictive modelling of cardiovascular disease risk

The risk of cardiovascular disease (CVD) is orchestrated by multiple factors. QRISK models (currently QRISK3) have been used in the UK to estimate CVD risk within the next 10 years for individuals without CVD. Read more

Molecular characterisation of a novel transporter for the atypical antipsychotic clozapine

Schizophrenia is a severe psychiatric illness affecting about 24 million people worldwide. Schizophrenia can have a devastating effect on a patient’s life and is associated with increased mortality, with life expectancy reduced on average by 15 years compared to that of the general population. Read more

Filtering Results